Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
J Cardiothorac Vasc Anesth. 2021 Apr;35(4):1073-1085. doi: 10.1053/j.jvca.2020.11.068. Epub 2020 Dec 2.
This meta-analysis aimed to systematically review the effects of etomidate (ETM) during anesthetic induction on patients undergoing cardiac surgery.
Systematic review and meta-analysis.
Operating room.
Patients undergoing cardiac surgery.
ETM or control drugs.
PubMed, Cochrane Library, OVID, and EMBASE were searched through August 31, 2020. Primary outcomes included hemodynamic profiles and stress responses. Secondary outcomes included morbidity, mortality, and postoperative recovery. For continuous/dichotomous variables, treatment effects were calculated as weighted mean difference (WMD)/odds ratio (OR) and 95% confidence interval (CI). A database search yielded 18 randomized controlled trials including 1,241 patients. The present meta-analysis demonstrated that ETM-anesthetized patients had lower heart rates (WMD, -3.31; 95% CI -5.43 to -1.19; p = 0.002), higher blood pressures (systolic blood pressure: WMD, 12.02; 95% CI 6.24 to 17.80; p < 0.0001; diastolic blood pressure: WMD, 5.23; 95% CI 2.39 to 8.08; p = 0.0003; mean arterial pressure (MAP): WMD, 8.64; 95% CI 5.85 to 11.43; p < 0.00001), less requirement for vasopressor (OR, 0.26; 95% CI 0.15 to 0.44; p < 0.00001), and more nitroglycerin usage (OR, 14.89; 95% CI 4.92 to 45.08; p < 0.00001) during anesthetic induction. Current meta-analysis also demonstrated that single-dose ETM lowered cortisol levels transiently and did not have a significant effect on endogenous norepinephrine and epinephrine levels and was not associated with increased postoperative inotrope and/or vasopressor requirement. Additionally, the meta-analysis suggested that ETM anesthesia was associated with neither increased mortality nor morbidity, except a higher incidence of transient adrenal insufficiency in ETM recipients.
The present meta-analysis suggested that single-dose ETM during anesthetic induction could be associated with more stable hemodynamics, transient and reversible lower cortisol levels, and a higher adrenal insufficiency incidence, but not worse outcomes in cardiac surgical patients.
本荟萃分析旨在系统评价麻醉诱导期间使用依托咪酯(ETM)对接受心脏手术患者的影响。
系统评价和荟萃分析。
手术室。
接受心脏手术的患者。
ETM 或对照药物。
通过 2020 年 8 月 31 日检索 PubMed、Cochrane 图书馆、OVID 和 EMBASE。主要结局包括血流动力学特征和应激反应。次要结局包括发病率、死亡率和术后恢复。对于连续性/二分类变量,治疗效果计算为加权均数差(WMD)/比值比(OR)和 95%置信区间(CI)。数据库搜索产生了 18 项随机对照试验,包括 1241 名患者。本荟萃分析表明,接受 ETM 麻醉的患者心率更低(WMD,-3.31;95%CI -5.43 至 -1.19;p=0.002),血压更高(收缩压:WMD,12.02;95%CI 6.24 至 17.80;p<0.0001;舒张压:WMD,5.23;95%CI 2.39 至 8.08;p=0.0003;平均动脉压(MAP):WMD,8.64;95%CI 5.85 至 11.43;p<0.00001),血管加压药需求更少(OR,0.26;95%CI 0.15 至 0.44;p<0.00001),并且在麻醉诱导期间使用硝酸甘油更多(OR,14.89;95%CI 4.92 至 45.08;p<0.00001)。目前的荟萃分析还表明,单次剂量 ETM 可使皮质醇水平短暂降低,但对内源性去甲肾上腺素和肾上腺素水平没有显著影响,与术后正性肌力药和/或血管加压药需求增加无关。此外,荟萃分析表明,除了 ETM 受体中更高的一过性肾上腺功能不全发生率外,ETM 麻醉与死亡率或发病率的增加无关。
本荟萃分析表明,麻醉诱导期间单次剂量 ETM 可能与更稳定的血流动力学、短暂和可逆的低皮质醇水平以及更高的肾上腺功能不全发生率相关,但与心脏手术患者的不良结局无关。